Wael Al Halaseh, MD
Cardiovascular Disease · Fort Payne, ALNPI 1760645311
Payments from drug & device makers
Across 127 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$738
- Acist Medical Systems, Inc.$393
- Amgen$229
- Novo Nordisk$148
- Boston Scientific$145
- E.r. Squibb & Sons, L.L.C.$100
- plus $262 from 11 others
What the payments were for
- Travel & lodging$39319%
- Food & beverage$1,60079%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 74 | $738 |
| Acist Medical Systems, Inc. | 1 | $393 |
| Amgen | 13 | $229 |
| Novo Nordisk | 8 | $148 |
| Boston Scientific | 13 | $145 |
| E.r. Squibb & Sons, L.L.C. | 4 | $100 |
| Impulse Dynamics (USA) Inc. | 2 | $48 |
| Pfizer | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Abiomed | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Abbott | 1 | $21 |
| AstraZeneca | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
| Merck | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HD-IVUS$393
How this compares
$2,015 in reported general payments places this provider in the 40th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,152 | $775,677 |
| Repatha SureclickEvolocumab | 620 | $364,774 |
| MounjaroTirzepatide | 288 | $334,920 |
| OzempicSemaglutide | 221 | $221,960 |
| AdempasRiociguat | 13 | $172,341 |
| EntrestoSacubitril/Valsartan | 183 | $139,605 |
| Repatha PushtronexEvolocumab | 183 | $124,276 |
| JardianceEmpagliflozin | 127 | $96,551 |
| XareltoRivaroxaban | 132 | $89,074 |
| FarxigaDapagliflozin Propanediol | 97 | $64,449 |
| NexlizetBempedoic Acid/Ezetimibe | 66 | $32,618 |
| JanuviaSitagliptin Phosphate | 39 | $31,103 |
| Ranolazine ErRanolazine | 341 | $23,795 |
| MultaqDronedarone Hcl | 16 | $18,567 |
| Prasugrel Hcl | 301 | $18,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $42 | $775,6771,152 claims |
| Lilly USA, LLCMounjaro | $22 | $334,920288 claims |
| Novo NordiskOzempic | $148 | $221,960221 claims |
| NovartisEntresto | $738 | $139,605183 claims |
| Boehringer IngelheimJardiance, Pradaxa | $14 | $99,400142 claims |
| AstraZenecaFarxiga | $17 | $64,44997 claims |
| MerckJanuvia, Verquvo | $13 | $47,91167 claims |
| Esperion Therapeutics, Inc.Nexlizet | $37 | $32,61866 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Fort Payne
- Mustafa AhmedBirmingham$2.5M
- Brian FoleyAlexander City$2.5M
- Andreas MuenchDothan$2M
- Alain BouchardBirmingham$1.9M
- William DavisAuburn$1.7M
- Walter HaughtHuntsville$1.6M
- Christopher BrownMobile$1.4M
- Shi-Chi ChengHuntsville$1.2M
- Mahomed SalameAnniston$1.2M
- Steven JonesBirmingham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.